CA2795438A1 - Method of detecting and profiling progression of the risk of neurodegenerative diseases - Google Patents

Method of detecting and profiling progression of the risk of neurodegenerative diseases Download PDF

Info

Publication number
CA2795438A1
CA2795438A1 CA2795438A CA2795438A CA2795438A1 CA 2795438 A1 CA2795438 A1 CA 2795438A1 CA 2795438 A CA2795438 A CA 2795438A CA 2795438 A CA2795438 A CA 2795438A CA 2795438 A1 CA2795438 A1 CA 2795438A1
Authority
CA
Canada
Prior art keywords
stem cell
determining
antibody
subject
disease
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA2795438A
Other languages
English (en)
French (fr)
Inventor
C. Shekhar Mayanil
Shunsuke Ichi
Tadanori Tomita
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Lurie Children's Hospital
Original Assignee
Lurie Children's Hospital
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lurie Children's Hospital filed Critical Lurie Children's Hospital
Publication of CA2795438A1 publication Critical patent/CA2795438A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2440/00—Post-translational modifications [PTMs] in chemical analysis of biological material
    • G01N2440/12—Post-translational modifications [PTMs] in chemical analysis of biological material alkylation, e.g. methylation, (iso-)prenylation, farnesylation
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2814—Dementia; Cognitive disorders
    • G01N2800/2821—Alzheimer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2835—Movement disorders, e.g. Parkinson, Huntington, Tourette
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/50—Determining the risk of developing a disease

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Neurology (AREA)
  • Immunology (AREA)
  • Neurosurgery (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Food Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • General Physics & Mathematics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Measuring And Recording Apparatus For Diagnosis (AREA)
  • Measurement Of The Respiration, Hearing Ability, Form, And Blood Characteristics Of Living Organisms (AREA)
CA2795438A 2010-05-11 2011-04-21 Method of detecting and profiling progression of the risk of neurodegenerative diseases Abandoned CA2795438A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US39532110P 2010-05-11 2010-05-11
US61/395,321 2010-05-11
PCT/US2011/033387 WO2011142952A1 (en) 2010-05-11 2011-04-21 Method of detecting and profiling progression of the risk of neurodegenerative diseases

Publications (1)

Publication Number Publication Date
CA2795438A1 true CA2795438A1 (en) 2011-11-17

Family

ID=44914644

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2795438A Abandoned CA2795438A1 (en) 2010-05-11 2011-04-21 Method of detecting and profiling progression of the risk of neurodegenerative diseases

Country Status (5)

Country Link
US (1) US20130029998A1 (enExample)
EP (1) EP2569625A4 (enExample)
JP (1) JP2013526705A (enExample)
CA (1) CA2795438A1 (enExample)
WO (1) WO2011142952A1 (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3302541A4 (en) 2015-06-03 2018-12-05 Aelan Cell Technologies Inc. Methods and devices for the production and delivery of beneficial factors from stem cells
US10282875B2 (en) 2015-12-11 2019-05-07 International Business Machines Corporation Graph-based analysis for bio-signal event sensing
WO2017184873A2 (en) 2016-04-20 2017-10-26 Aelan Cell Technologies, Inc. Compositions and methods related to the methylation of histone h1.0 protein
JP7136790B2 (ja) 2017-02-17 2022-09-13 ブリストル－マイヤーズ スクイブ カンパニー アルファ－シヌクレインに対する抗体およびその使用
JP7252953B2 (ja) * 2017-10-25 2023-04-05 エアラン セル テクノロジーズ， インコーポレイテッド Ｈ１．０ｋ１８０ｍｅ２抗体、その作製および使用の方法

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7025A (en) * 1850-01-15 Buckle
US11016A (en) * 1854-06-06 Method of turning hubs
US20050037992A1 (en) * 2003-07-22 2005-02-17 John Lyons Composition and method for treating neurological disorders
JP2011504462A (ja) * 2007-11-02 2011-02-10 エージェンシー フォー サイエンス，テクノロジー アンド リサーチ 腫瘍の予防および治療のための方法および化合物
WO2010001933A1 (ja) * 2008-07-01 2010-01-07 学校法人日本大学 標的遺伝子特異的ヒストン修飾制御剤

Also Published As

Publication number Publication date
EP2569625A4 (en) 2013-12-04
WO2011142952A1 (en) 2011-11-17
JP2013526705A (ja) 2013-06-24
US20130029998A1 (en) 2013-01-31
EP2569625A1 (en) 2013-03-20

Similar Documents

Publication Publication Date Title
Guan et al. Decreased protein levels of nicotinic receptor subunits in the hippocampus and temporal cortex of patients with Alzheimer’s disease
Gibbons et al. Detection of Alzheimer disease (AD)-specific tau pathology in AD and nonAD tauopathies by immunohistochemistry with novel conformation-selective tau antibodies
Hamilton et al. Widespread deficits in adult neurogenesis precede plaque and tangle formation in the 3xTg mouse model of Alzheimer’s disease
Nijholt et al. The unfolded protein response is associated with early tau pathology in the hippocampus of tauopathies
Rodríguez-Martín et al. Tau phosphorylation affects its axonal transport and degradation
Regad et al. The tumor suppressor Pml regulates cell fate in the developing neocortex
Aydemir et al. The effect of chronic antidepressant treatment on serum brain-derived neurotrophic factor levels in depressed patients: a preliminary study
CN103154736B (zh) 用于检测和诊断神经变性疾病的诊断性自身抗体谱
US20130029998A1 (en) Method of Detecting and Profiling Progression of the Risk of Neurodegenerative Diseases
Wenk et al. Altered cholinergic function in the basal forebrain of girls with Rett syndrome
Swenson et al. Senescence in aging and disorders of the central nervous system
Mazzetti et al. Astrocytes expressing Vitamin D‐activating enzyme identify Parkinson’s disease
EP1339743A2 (en) Compositions and methods for diagnosing alzheimer's disease
JP5642687B2 (ja) 神経学的な自己免疫性障害
Min et al. Insulin‐like growth factor I regulates G2/M progression through mammalian target of rapamycin signaling in oligodendrocyte progenitors
Liu et al. Calcium sensing receptor absence delays postnatal brain development via direct and indirect mechanisms
Melamud et al. Neuromyelitis Optica Immunoglobulin G present in sera from neuromyelitis optica patients affects aquaporin‐4 expression and water permeability of the astrocyte plasma membrane
Mukaetova-Ladinska et al. Alpha-and gamma-synuclein proteins are present in cerebrospinal fluid and are increased in aged subjects with neurodegenerative and vascular changes
Bernstein et al. Partial loss of parvalbumin‐containing hippocampal interneurons in dementia with Lewy bodies
Teunissen et al. Growth‐associated protein 43 in lesions and cerebrospinal fluid in multiple sclerosis
EP4084827A1 (en) Kinases as biomarkers for neurodegenerative conditions
Costa et al. Galanin and α-MSH autoantibodies in cerebrospinal fluid of patients with Alzheimer's disease
US20150025008A1 (en) Compositions and Methods of Detecting and Treating Neural Tube Defects
Iacono et al. Reduced number of pigmented neurons in the substantia nigra of dystonia patients? Findings from extensive neuropathologic, immunohistochemistry, and quantitative analyses
CN105277715A (zh) 巨噬细胞迁移抑制因子(mif)作为早期阿尔茨海默病血清分子标志物

Legal Events

Date Code Title Description
EEER Examination request
FZDE Dead

Effective date: 20160421